Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Santiago Ferrer Bazaga"'
Autor:
Paul M. O’Neill, Richard K. Amewu, Susan A. Charman, Sunil Sabbani, Nina F. Gnädig, Judith Straimer, David A. Fidock, Emma R. Shore, Natalie L. Roberts, Michael H.-L. Wong, W. David Hong, Chandrakala Pidathala, Chris Riley, Ben Murphy, Ghaith Aljayyoussi, Francisco Javier Gamo, Laura Sanz, Janneth Rodrigues, Carolina Gonzalez Cortes, Esperanza Herreros, Iñigo Angulo-Barturén, María Belén Jiménez-Díaz, Santiago Ferrer Bazaga, María Santos Martínez-Martínez, Brice Campo, Raman Sharma, Eileen Ryan, David M. Shackleford, Simon Campbell, Dennis A. Smith, Grennady Wirjanata, Rintis Noviyanti, Ric N. Price, Jutta Marfurt, Michael J. Palmer, Ian M. Copple, Amy E. Mercer, Andrea Ruecker, Michael J. Delves, Robert E. Sinden, Peter Siegl, Jill Davies, Rosemary Rochford, Clemens H. M. Kocken, Anne-Marie Zeeman, Gemma L. Nixon, Giancarlo A. Biagini, Stephen A. Ward
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-10 (2017)
Artemisinin-resistantPlasmodium is an increasing problem. Here, using a medicinal chemistry programme, the authors identify a tetraoxane-based drug candidate that shows no cross-resistance with an artemisinin-resistant strain (PfK13-C580Y) and is eff
Externí odkaz:
https://doaj.org/article/d0b09995908d4fd1a466aa398f702f2f
Autor:
Laura Sibley, Andrew D. White, Charlotte Sarfas, Jennie Gullick, Fergus Gleeson, Faye Lanni, Simon Clark, Emma Rayner, Santiago Ferrer-Bazaga, Fatima Ortega-Muro, Laura Alameda, Joaquin Rullas, Veronica Sousa, Marisa Martinez, Inigo Angulo-Barturen, Adolfo Garcia, Juan José Vaquero, Henry E. Pertinez, Geraint Davies, Mike Dennis, Ann Williams, Sally Sharpe
Publikováno v:
Pharmaceutics, Vol 14, Iss 12, p 2666 (2022)
Innovative cross-over study designs were explored in non-human primate (NHP) studies to determine the value of this approach for the evaluation of drug efficacy against tuberculosis (TB). Firstly, the pharmacokinetics (PK) of each of the drugs Isonia
Externí odkaz:
https://doaj.org/article/de04d1d2aadf4dc2bc3352fe889680e3
Autor:
Andrew A Voak, Andy Harris, Jose Miguel Coteron-Lopez, Iñigo Angulo-Barturen, Santiago Ferrer-Bazaga, Simon L Croft, Karin Seifert
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 15, Iss 3, p e0009013 (2021)
BackgroundThere is a continued need to develop effective and safe treatments for visceral leishmaniasis (VL). Preclinical studies on pharmacokinetics and pharmacodynamics of anti-infective agents, such as anti-bacterials and anti-fungals, have provid
Externí odkaz:
https://doaj.org/article/47a6dab74561481094f814b179a5266f
Autor:
Vlatka Bencetić Mihaljević, Andrea Fajdetić, Jasna Padovan, Domingo Gargallo-Viola, Amanda Mathis, Esperanza Herreros, Mihailo Banjanac, María Santos Martínez, Radan Spaventi, Albane Kessler, Iñigo Angulo-Barturen, Mihaela Perić, Vesna Eraković Haber, Vesna Munic Kos, Santiago Ferrer-Bazaga, Sulejman Alihodžić, María Belén Jiménez-Díaz, Dijana Pesic, Francisco-Javier Gamo, Mirjana Bukvić
Publikováno v:
British journal of pharmacology. 178(2)
Background and purpose: Efficacy of current antimalarial treatments is declining as a result of increasing antimalarial drug resistance, so new and potent antimalarial drugs are urgently needed. Azithromycin, an azalide antibiotic, was found useful i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a230fcc3129988b988dd1906910df64
https://pubmed.ncbi.nlm.nih.gov/33085774
https://pubmed.ncbi.nlm.nih.gov/33085774
Autor:
Elena Sandoval, Maria Santos Martinez-Martinez, Beatriz Hernández Díaz, Esther Fernández, Maria Jose Lafuente-Monasterio, Jeremy N. Burrows, Simon J. F. Macdonald, Sara Prats, John N. Haselden, Gerard Drewes, Pablo Castañeda, Francisco J. Gamo, J. Vidal, Jose Ignacio Martin Hernando, Benigno Crespo, Margarita Puente, David Matthew Wilson, Paul Bamborough, María Luisa León, Maria Jesus Almela, Sonja Ghidelli-Disse, Rubén M. Gómez, Jaime de Mercado, Carolyn Selenski, Jose M. Coteron, Anne Rodríguez, Cristina de Cozar, Michael J Witty, Juan C. de la Rosa, Paul Willis, Iñigo Angulo-Barturen, María J. Chaparro, Lourdes Rueda, Félix Calderón, Nicholas Cammack, Santiago Ferrer-Bazaga, Sophie Huss, María T. Fraile, María Belén Jiménez Díaz
Publikováno v:
Journal of Medicinal Chemistry. 60:6880-6896
Since the appearance of resistance to the current front-line antimalarial treatments, ACTs (artemisinin combination therapies), the discovery of novel chemical entities to treat the disease is recognized as a major global health priority. From the GS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acfce1c3bf707c62527d304e5e25cb21
https://doi.org/10.1021/acs.jmedchem.6b01441
https://doi.org/10.1021/acs.jmedchem.6b01441
Autor:
Santiago Ferrer-Bazaga, Karin Seifert, Jose Miguel Coteron-Lopez, Iñigo Angulo-Barturen, Simon L. Croft, Andrew A. Voak, Andrew G. Harris
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 15, Iss 3, p e0009013 (2021)
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases
Background There is a continued need to develop effective and safe treatments for visceral leishmaniasis (VL). Preclinical studies on pharmacokinetics and pharmacodynamics of anti-infective agents, such as anti-bacterials and anti-fungals, have provi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca5bbd117770bd9e5160285e45a7890
https://doi.org/10.1371/journal.pntd.0009013
https://doi.org/10.1371/journal.pntd.0009013
Autor:
Krishne Manjalanagara, Margaret A. Phillips, Xiaoyi Deng, Michael Campbell, Karen L. White, Ric N. Price, Kennan C. Marsh, Jeremy N. Burrows, John H. White, Werner Kaminsky, Anne Marie Zeeman, Sreekanth Kokkonda, Susan A. Charman, Diana R. Tomchick, Santiago Ferrer Bazaga, Clemens H. M. Kocken, Grennady Wirjanata, Francis C. K. Chiu, María Santos Martínez, David M. Shackleford, María Belén Jiménez-Díaz, Kigbafori D. Silué, Thomas Rueckle, Jutta Marfurt, Kakali Rani Rudra, Benjamin Blasco, Iñigo Angulo-Barturen, Rintis Noviyanti, Pradipsinh K. Rathod, Maria J. Lafuente-Monasterio, Michael J. Palmer, Dave Matthews, Emilie Rossignol, David Waterson, Didier Leroy, Farah El Mazouni
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The emergence of drug-resistant malaria parasites continues to hamper efforts to control this lethal disease. Dihydroorotate dehydrogenase has recently been validated as a new target for the treatment of malaria, and a selective inhibitor (DSM265) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d851b9d4cb13df52510a17dca85e3e7
https://doi.org/10.1021/acsinfecdis.6b00144
https://doi.org/10.1021/acsinfecdis.6b00144
Autor:
Jeremy N. Burrows, María Belén Jiménez-Díaz, John H. White, Maria L. Marco, Maria Santos Martinez-Martinez, Sreekanth Kokkonda, Margaret A. Phillips, David Waterson, Laura Fernández de las Heras, Xiaoyi Deng, Iñigo Angulo-Barturen, Farah El Mazouni, Kakali Rani Rudra, Julia Morizzi, Santiago Ferrer Bazaga, Gong Chen, Didier Leroy, Pradipsinh K. Rathod, Diana R. Tomchick, Karen L. White, Eileen Ryan, Jose M. Coteron, Dave Matthews, Werner Kaminsky, Krishne Manjalanagara, Susan A. Charman
Publikováno v:
Journal of Medicinal Chemistry
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Malaria persists as one of the most devastating global infectious diseases. The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) has been identified as a new malaria drug target, and a triazolopyrimidine-based DHODH inhibitor 1 (DS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d025ce92b9638f02bef4e58dbca9749e
http://europepmc.org/articles/PMC4904246
http://europepmc.org/articles/PMC4904246
Publikováno v:
Journal of Infectious Diseases. 211:S96-S106
Background Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science is vital to early antibiotic drug development to enable more efficient dose-effect study designs, identification of doses that may suppress drug resistance and choice of suscept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c124b75766832e94ab27efecf0a5e7
https://doi.org/10.1093/infdis/jiu610
https://doi.org/10.1093/infdis/jiu610
Autor:
Paul Willis, Elena Sandoval, Carolyn Selenski, Michael J Witty, Maria Jesus Almela, Jaime de Mercado, Sonja Ghidelli-Disse, Jeremy N. Burrows, Simon J. F. Macdonald, Anne Rodríguez, Santiago Ferrer-Bazaga, Cristina de Cozar, Beatriz Hernández Díaz, Paul Bamborough, Sara Prats, Rubén M. Gómez, María Belén Jiménez Díaz, Maria Jose Lafuente-Monasterio, Iñigo Angulo-Barturen, Margarita Puente, David M. Wilson, Jose M. Coteron, Juan C. de la Rosa, Pablo Castañeda, María Luisa León, Francisco J. Gamo, Jose Ignacio Martin Hernando, John N. Haselden, María J. Chaparro, Sophie Huss, María T. Fraile, Lourdes Rueda, Félix Calderón, Nicholas Cammack, Maria Santos Martinez-Martinez, Gerard Drewes, J. Vidal, Benigno Crespo, Esther Fernández
Publikováno v:
Journal of medicinal chemistry. 60(23)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca0175d454f38a34fcaa02c5eae30f5
https://pubmed.ncbi.nlm.nih.gov/28806082
https://pubmed.ncbi.nlm.nih.gov/28806082